VistaGen Therapeutics

Vistagen's PH284 Nasal Spray Shows Promise in Treating Cancer Cachexia

4 months ago

• Vistagen announced positive Phase 2A results for PH284 nasal spray in cancer cachexia, showing improved hunger feelings. • The study revealed a 71% increase in subjective hunger feeling in PH284-treated patients versus minimal improvement in the placebo group. • PH284 demonstrated a favorable safety profile, with adverse events similar to placebo and no unusual changes in body weight observed. • Vistagen is assessing the path forward for PH284, potentially including a U.S. Investigational New Drug application for further Phase 2 trials.

VistaGen's Anxiety Drug Trials Maintain Stifel's Optimism

6 months ago

• VistaGen Therapeutics is progressing with Phase 3 clinical trials for fasedienol, a drug candidate for Social Anxiety Disorder (SAD). • Stifel reiterated a Buy rating on VistaGen's stock, citing the potential success of the PAL-3 and PAL-4 trials. • VistaGen is also advancing itruvone into Phase 2b trials and preparing for a U.S. IND submission for PH80 for menopausal hot flashes. • The company's shares are trading near cash value, presenting a favorable risk/reward balance according to Stifel.

VistaGen's Fasedienol Shows Promise in Phase 3 Trials for Social Anxiety Disorder

6 months ago

• VistaGen's Phase 3 trials for fasedienol in acute social anxiety disorder are progressing, with PALISADE-4 active and results expected from PALISADE-3 and PALISADE-4 in 2025. • The Phase 2 PALISADE-2 trial demonstrated significant positive results, supporting the ongoing Phase 3 studies for fasedienol in treating social anxiety disorder. • VistaGen is also advancing itruvone for major depressive disorder, with a Phase 2b study planned after encouraging Phase 2a results, expanding its pipeline. • With a cash reserve of $97.6 million, VistaGen is financially stable through fiscal year 2026, supporting its clinical development programs.